166 related articles for article (PubMed ID: 38409035)
1. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.
Da X; Cao B; Mo J; Xiang Y; Hu H; Qiu C; Zhang C; Lv B; Zhang H; He C; Yang Y
BMC Cancer; 2024 Feb; 24(1):273. PubMed ID: 38409035
[TBL] [Abstract][Full Text] [Related]
2. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.
Ke Y; Xiang C
Int J Nanomedicine; 2018; 13():8339-8354. PubMed ID: 30584304
[TBL] [Abstract][Full Text] [Related]
3. Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers.
Da X; Mo J; Li Q; Cao B; Huang J; Lu Y; Lu L; Fan M; Lu H
Biochem Biophys Res Commun; 2023 Sep; 671():335-342. PubMed ID: 37327705
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
6. Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7.
Yousef EH; Abo El-Magd NF; El Gayar AM
Life Sci; 2023 Jul; 324():121735. PubMed ID: 37142088
[TBL] [Abstract][Full Text] [Related]
7. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery.
Wang H; Wu J; Williams GR; Fan Q; Niu S; Wu J; Xie X; Zhu LM
J Nanobiotechnology; 2019 May; 17(1):60. PubMed ID: 31084622
[TBL] [Abstract][Full Text] [Related]
8. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S; Hiraoka A; Nakano M; Iwamoto H; Tanaka M; Tanaka T; Noguchi K; Aino H; Ogata K; Kajiwara M; Itano S; Yokokura Y; Yamaguchi T; Kawano H; Matsukuma N; Suga H; Niizeki T; Shirono T; Noda Y; Kamachi N; Okamura S; Kawaguchi T; Koga H; Torimura T
Cancer Med; 2021 Dec; 10(23):8530-8541. PubMed ID: 34693661
[TBL] [Abstract][Full Text] [Related]
9. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
10. KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Kuang Y; Cheng Y; Wang J; Li H; Cao X; Wang Y
Cancer Med; 2023 Mar; 12(6):7222-7233. PubMed ID: 36420693
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
12. Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma.
Wu L; Xie W; Zan HM; Liu Z; Wang G; Wang Y; Liu W; Dong W
J Mater Chem B; 2020 Jun; 8(21):4648-4659. PubMed ID: 32373904
[TBL] [Abstract][Full Text] [Related]
13. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.
Niu B; Wei S; Sun J; Zhao H; Wang B; Chen G
Pharm Biol; 2022 Dec; 60(1):75-86. PubMed ID: 34962429
[TBL] [Abstract][Full Text] [Related]
14. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
16. Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma.
Chen Y; Li N; Xu B; Wu M; Yan X; Zhong L; Cai H; Wang T; Wang Q; Long F; Jiang G; Xiao H
Biomed Pharmacother; 2019 Oct; 118():109257. PubMed ID: 31377472
[TBL] [Abstract][Full Text] [Related]
17. Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway.
Yousef EH; El-Magd NFA; El Gayar AM
Transl Res; 2023 Oct; 260():69-82. PubMed ID: 37257560
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
19. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
[TBL] [Abstract][Full Text] [Related]
20. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
[No Abstract] [Full Text] [Related]
[Next] [New Search]
